Press Releases Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:12 12/12/2025 GMT			5-day change	1st Jan Change
316.80 ^CHF	-0.35%		+1.90%	+23.99%

12-12	US FDA approves Innoviva's oral antibiotic for gonorrhea	RE
12-12	Natera and MEDSIR to Collaborate on the Mirador Trial in Breast Cancer	CI

Press Releases

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer	12-10	BU
Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas	12-08	BU
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer	11-18	BU
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis	11-10	BU
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025	11-03	BU
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus	11-03	BU
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome	10-28	BU
Roche : Nine-month 2025 Presentation	10-23	PU
Roche : Nine-month 2025 Presentation with appendix	10-23	PU
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment	10-20	BU
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis	10-20	BU
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer	10-18	BU
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss	10-17	BU
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch	10-16	BU
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types	10-13	BU
Fitch Affirms Novartis at 'AA-'; Outlook Stable; Withdraws Ratings	10-09	AQ
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	10-02	BU
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025	09-24	BU
Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer	09-22	BU
Roche pays $3.5bn for 89bio and its potential best-in-disease treatment MASH drug	09-18	AQ
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)	09-05	BU
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension	08-30	BU
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina	08-25	BU
Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)	08-01	BU
Genentech and Roche Present New Insights in Alzheimer’s Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC	07-28	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ROCHE HOLDING : Markets need more proof of potential; guidance upgrade apparently won't cut it

October 23, 2025 at 04:05 pm

Roche will invest $50bn in US over five years.

April 22, 2025 at 09:49 am

Roche CEO 'Very Confident' on Outlook, Momentum

October 23, 2024 at 09:07 am